Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, jco2400767. PMID: 39255440, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian follow-upPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibAdjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma
Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, Pruthi D, Bergerot C, Tripathi A, Lerner S, Thompson I, Lara P, Pal S. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma. JAMA Network Open 2024, 7: e2425288. PMID: 39106067, PMCID: PMC11304111, DOI: 10.1001/jamanetworkopen.2024.25288.Peer-Reviewed Original ResearchConceptsChromophobe renal cell carcinomaRecurrence-free survivalPapillary renal cell carcinomaRenal cell carcinomaNon-clear cell renal cell carcinomaResected renal cell carcinomaCell renal cell carcinomaOverall survivalWeeks of treatmentCell carcinomaAdverse eventsClinical trialsHazard ratioPhase 3 randomized clinical trialWeeks of everolimusHigher adverse eventsRate of adverse eventsIntermediate-high riskIntervention groupVery-high-riskCox regression modelsPotential treatment benefitsClinical trial dataTreatment-naivePartial nephrectomyBone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer
Gebrael G, Jo Y, Swami U, Plets M, Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2419966. PMID: 38980676, PMCID: PMC11234233, DOI: 10.1001/jamanetworkopen.2024.19966.Peer-Reviewed Original ResearchConceptsProgression-free survivalAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerBone painOverall survivalPost hoc secondary analysisProstate cancerSurvival outcomesPain statusAssociated with shorter progression-free survivalClinical trialsPresence of bone painProstate-specific antigen levelAssociated with worse overall survivalCastration-resistant prostate cancerShorter progression-free survivalIntention-to-treat populationSecondary analysisZubrod performance statusHigh-volume diseaseCompare survival outcomesCox proportional hazards regression modelsSecondary end pointsProportional hazards regression modelsPredicting clinical outcomes in the S1314-COXEN trial using a multimodal deep learning model integrating histopathology, cell types, and gene expression.
Faltas B, Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Wang F. Predicting clinical outcomes in the S1314-COXEN trial using a multimodal deep learning model integrating histopathology, cell types, and gene expression. Journal Of Clinical Oncology 2024, 42: 533-533. DOI: 10.1200/jco.2024.42.4_suppl.533.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to NACNeoadjuvant chemotherapyPathological response to NACOutcomes of neoadjuvant chemotherapyResponse to neoadjuvant chemotherapyPrediction of response to neoadjuvant chemotherapyCell typesNAC responseDevelopment of precision therapiesOptimize treatment outcomesGene set analysisPredicting cell typesGemcitabine-cisplatinRNA expression dataTumor microenvironmentPathological responseBladder cancerClinical outcomesGene expression vectorPrecision therapyClinical trialsTreatment outcomesStromal cellsBasal differentiationSWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).
Maughan B, Plets M, Pal S, Ged Y, Tangen C, Vaishampayan U, Lerner S, Thompson I. SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC). Journal Of Clinical Oncology 2024, 42: tps493-tps493. DOI: 10.1200/jco.2024.42.4_suppl.tps493.Peer-Reviewed Original ResearchPapillary renal cell carcinomaProgression free survivalMedian progression free survivalImmune therapyAdvanced papillary renal cell carcinomaComparison of progression free survivalClinical trialsPhase II randomized trialObjective response rateLines of therapyPresence of metastasesRenal cell carcinomaSignificant autoimmune diseaseSingle arm trialRandomized clinical trialsStandard of careAdjuvant pembrolizumabFree survivalMetastatic diseaseOverall survivalCell carcinomaPrimary endpointPathological confirmationSecondary endpointsTargeted therapy